Cargando…

Comparison of oxidative stress markers in HIV-infected patients on efavirenz or atazanavir/ritonavir-based therapy

INTRODUCTION: Chronic low-grade inflammation and immune activation may persist in HIV patients despite effective antiretroviral therapy (ART). These abnormalities are associated with increased oxidative stress (OS). Bilirubin (BR) may have a beneficial role in counteracting OS. Atazanavir (ATV) inhi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Estrada, Vicente, Monge, Susana, Gómez-Garre, Dulcenombre, Sobrino, Paz, Berenguer, Juan, Ignacio Bernardino, Jose, Santos, Jesús, Moreno Zamora, Ana, Martínez, Esteban, Ramón Blanco, Jose
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International AIDS Society 2014
Materias:	Poster Sessions – Abstract P012
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4224902/ https://www.ncbi.nlm.nih.gov/pubmed/25394051 http://dx.doi.org/10.7448/IAS.17.4.19544

Ejemplares similares

Le risque de transmission du SARS-CoV-2 par le sang et les produits sanguins : l’état actuel des connaissances
por: Bouhou, Sabah, et al.
Publicado: (2021)

Efficacy of a dual therapy based on darunavir/ritonavir and etravirine in ART-experienced patients
por: Ignacio Bernardino, Jose, et al.
Publicado: (2014)

ASPECTOS EPIDEMIOLÓGICOS E CLÍNICO-EVOLUTIVOS DE UMA COORTE DE PACIENTES INTERNADOS COM COVID-19 NO HC-UNICAMP. OCORRÊNCIA DE EVENTOS ADVERSOS E FATORES RELACIONADOS AO PROGNÓSTICO
por: Luz, Maitê Vasconcelos, et al.
Publicado: (2022)

Targeting Vascular Leakage for Novel Biomarker Diagnosis and Therapy of Severe Pulmonary Infections
por: Li, L., et al.
Publicado: (2018)

COINFECÇÃO POR LEISHMANIOSE E PARACOCCIDIOIDOMICOSE E COMPLICAÇÕES TROMBÓTICAS GRAVES POR COVID‐19: RELATO DE CASO
por: Santos, Rômulo Pereira, et al.
Publicado: (2021)

Risque de vascularites systémiques après une vaccination anti-SARS-CoV-2 à base d’ARN : une étude de pharmacovigilance
por: Mettler, C., et al.
Publicado: (2022)

COINFECÇÃO HIV E SARS-COV-2: UM PROGNÓSTICO RESERVADO?
por: da Silva, Júlia Gomes, et al.
Publicado: (2022)

Lp-PLA2 levels in HIV-infected patients
por: Díaz-Pollán, Beatriz, et al.
Publicado: (2014)

Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trial
por: Fabbiani, Massimiliano, et al.
Publicado: (2014)

Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT study
por: Spagnuolo, Vincenzo, et al.
Publicado: (2014)

Population Pharmacokinetics Modeling of Unbound Efavirenz, Atazanavir, and Ritonavir in HIV‐Infected Subjects With Aging Biomarkers
por: Dumond, JB, et al.
Publicado: (2016)

Serum lipid profiles among patients initiating ritonavir-boosted atazanavir versus efavirenz-based regimens
por: Ganesan, Anuradha, et al.
Publicado: (2009)

HIV-Tat Exacerbates the Actions of Atazanavir, Efavirenz, and Ritonavir on Cardiac Ryanodine Receptor (RyR2)
por: Alomar, Fadhel A., et al.
Publicado: (2022)

Unboosted atazanavir with lamivudine/emtricitabine for patients with long-lasting virological suppression
por: Carbone, Alessia, et al.
Publicado: (2014)

No difference in persistence to treatment with atazanavir or darunavir in HIV patients in a real-world setting
por: Farr, Amanda M, et al.
Publicado: (2014)

Monotherapy with darunavir/ritonavir is effective and safe in clinical practice
por: Pasquau, Juan, et al.
Publicado: (2014)

Atazanavir/efavirenz/lamivudine: Covid-19: case report
Publicado: (2021)

Nephrolithiasis and renal failure among patients exposed to atazanavir, other PIs and PI-free regimens
por: Nkhoma, Ella, et al.
Publicado: (2014)

Cerebral volumes, neuronal integrity and brain inflammation measured by MRI in patients receiving PI monotherapy or triple therapy
por: Pérez Valero, Ignacio, et al.
Publicado: (2014)

Factors involved in treatment durability and immunological recovery in a cohort of HIV-positive patients receiving atazanavir-based regimens
por: Giacomelli, Andrea, et al.
Publicado: (2014)

Boosted lopinavir vs boosted atazanavir in patients failing a NNRTI first line regimen in an urban clinic in Kampala
por: Laker, Eva, et al.
Publicado: (2014)

Lamivudine plus darunavir boosted with ritonavir as simplification dual regimen in HIV-infected patients
por: Luis Casado, Jose, et al.
Publicado: (2014)

Long term effectiveness of once-daily unboosted atazanavir plus abacavir/lamivudine as a switch strategy in subjects with virological suppression
por: Llibre, Josep M, et al.
Publicado: (2014)

Resistance mutations in protease gene at baseline are not related to virological failure in patients treated with darunavir/ritonavir monotherapy
por: Gutierrez-Liarte, Angela, et al.
Publicado: (2014)

Comparison of atazanavir/ritonavir and darunavir/ritonavir based antiretroviral therapy for antiretroviral naïve patients
por: Antoniou, Tony, et al.
Publicado: (2017)

Outcomes related to 4864 pregnancies with exposure to lopinavir/ritonavir (LPV/r)
por: Tookey, Pat, et al.
Publicado: (2014)

Acute development of Cushing syndrome in an HIV-infected child on atazanavir/ritonavir based antiretroviral therapy
por: Dubrocq, Gueorgui, et al.
Publicado: (2017)

Co-administration of ritonavir-boosted protease inhibitors and rate of tenofovir discontinuation in clinical practice
por: Costarelli, Silvia, et al.
Publicado: (2014)

Prospective evaluation of bone markers, parathormone and 1,25-(OH)(2 )vitamin D in HIV-positive patients after the initiation of tenofovir/emtricitabine with atazanavir/ritonavir or efavirenz
por: Focà, Emanuele, et al.
Publicado: (2012)

Serum Lipid Profiles of Patients Taking Efavirenz-Based Antiretroviral Regimen Compared to Ritonavir-Boosted Atazanavir with an Optimized Background at Zewditu Memorial Hospital, Addis Ababa, Ethiopia
por: Muche Belete, Abebe, et al.
Publicado: (2021)

Metabolic: week 48 comparison of metabolic parameters and biomarkers in subjects receiving darunavir/ritonavir or atazanavir/ritonavir
por: Overton, T, et al.
Publicado: (2010)

Comparative gender analysis of the efficacy and safety of atazanavir/ritonavir and lopinavir/ritonavir at 96 weeks in the CASTLE study
por: Squires, Kathleen E., et al.
Publicado: (2011)

Ritonavir-Boosted Darunavir Is Rarely Associated with Nephrolithiasis Compared with Ritonavir-Boosted Atazanavir in HIV-Infected Patients
por: Nishijima, Takeshi, et al.
Publicado: (2013)

Cerebrospinal-fluid exposure of efavirenz and its major metabolites when dosed at 400 and 600 mg once daily; a randomized controlled trial
por: Winston, Alan, et al.
Publicado: (2014)

Facial emotional processing deficits in long-term HIV-suppressed patients
por: Gonzalez-Baeza, Alicia, et al.
Publicado: (2014)

Overall and cause-specific mortality in HIV-positive subjects compared to the general population
por: Alejos, Belen, et al.
Publicado: (2014)

Cost-effectiveness of atazanavir-ritonavir versus lopinavir-ritonavir in HIV patients initiating first-line antiretroviral therapy
por: Broder, MS, et al.
Publicado: (2010)

Safety and Tolerability of High Dose Atazanavir–Ritonavir and Lopinavir–Ritonavir in Pregnant Women Living with Human Immunodeficiency Virus
por: McLaughlin, Milena M, et al.
Publicado: (2017)

Durability of lopinavir/ritonavir dual-therapies in individuals with viral load <50 copies/mL in the observational setting
por: Gianotti, Nicola, et al.
Publicado: (2014)

Switching from ritonavir to cobicistat in HIV patients with renal impairment who are virologically suppressed on a protease inhibitor
por: Fisher, Martin, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_omfitvqfbp5q7prrbrm7kqt2ik